Skip to content

Prospective study into the effect of an intraocular injection of a steroid in the prevention of Glaucoma drainage surgery failure after cataract surgery

Prospective randomised trial of intravitreal triamcinolone in the prevention of trabeculectomy failure after cataract surgery

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12611000336987
Enrollment
110
Registered
2011-03-31
Start date
2011-06-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Trabeculectomy surgery for Glaucoma establishes a connection between the inside of the eye and the subconjunctival space which lies just below the surface of the eye. Flow of fluid through this connection forms a subconjunctival blister known as a bleb. Aqueous humor (fluid inside the front of the eye )is absorbed from the bleb into the blood stream. A significant casue of failure of trabeculectomy is scarring of the bleb. If the bleb develops an excessive amount of scar tissue then fluid is prevented from exiting and the eye pressure is increased. Cataract surgery has been shown in research trials to increase the risk of trabeculectomy failure. Control of postoperative scar formation after cataract surgery is a significant challenge in the surgical management of glaucoma in patients who have had previous Trabeculectomy surgery. Current practice is to use topical steroids and antiscarring agents such as 5-fluorouracil (5-FU). Although the use of 5-FU is widespread, scar tissue remains a problem in many patients and treatment is associated with side effects including wound leaks and disruption of the ocular surface. Active scarring is associated with inflammation. Triamcinolone is a synthetic corticosteroid that inhibits the inflammatory process and may therefore reduce scar formation. Injection of triamcinolone into the vitreous jelly of the eye has been widely used as a treatment for various diabetic and inflammatory conditions which are unresponsive to topical corticosteroids. It has been used as a mono-therapy and co-therapy for various back of eye conditions, and is also indicated for visualisation during vitrectomy.

Interventions

A single injection of intravitreal injection of Triamcinolone acetonide (4mg in 0.1ml) in conjunction with 5-Fluorouracil (5mg in 0.1ml) injected superior to the Glaucoma filtration bleb

Sponsors

Royal Victorian Eye and Ear
Lead SponsorHospital

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
40 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

Patients with a functioning glaucoma filtration bleb who are due to undergo cataract surgery with intra-ocular lens implantation.

Exclusion criteria

Active or recent bleb leak, known hypersensitivity to 5-FU or Triamcinolone, only eye, active or recent blebitis or endophthalmitis.Previous vitrectomy. Previous retinal detachment or tear. Inability to give informed consent. Inability to be safely administeedr an intravitreal injection.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026